Taking into consideration that HOXA9 is not essential for normal development (So et al., 2004; Lawrence et al., 2005; Smith et al., 2011), PARP inhibitors would appear to have a great therapeutic potential in leukemia with MLL-rearrangements. This evidence concerns the gene KMT2A and leukemia.